You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Roivant reported $31 million in Lishraya net revenue during five weeks on market and said IMVG-1402 hit the primary endpoint in period two of a rheumatoid arthritis withdrawal study.
Roivant Sciences Ltd. said LISRAYA generated $31.0 million in its first 5 weeks after its August 2026 U.S. launch. Consolidated cash, cash equivalents and marketable securities totaled $4.2 billion as of September 30, 2026, supporting cash runway into profitability.
Roivant Sciences Ltd. reported that LISRAYA generated $31.0 million in net product revenue during its first 5 weeks of launch, and consolidated cash, cash equivalents and marketable securities totaled $4.2 billion as of September 30, 2026.
Roivant Sciences Ltd. announced positive Phase 3 CLARITY-1 and CLARITY-2 results for brepocitinib in non-infectious uveitis, including statistically significant primary and key secondary endpoint benefits. Priovant plans an sNDA in the first half of calendar year 2027.
Roivant is pursuing a slow-and-steady brepacitinib launch, preparing non-infectious uveitis registration if phase three data succeed, and prioritizing new indication studies across its portfolio.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Roivant reported Q1 FY2026 results with $3.9B in cash (excluding the $950M Moderna settlement payment received in July), received the initial Moderna settlement funds, advanced brepocitinib toward a potential DM launch by end of September 2026 and initiated a Phase 3 in cutaneous sarcoidosis, and remains on track for multiple second-half 2026 readouts (NIU, PH-ILD, CLE).
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gain on litigation settlement | $0.4M | the three months ended June 30, 2026 filing | — |
| Share-based compensation expense related to subsidiary EIPs | $14.8M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ROIV
this stock
Roivant Sciences Ltd.
|
$28.64B | +82.2% | -71.6% | — | 6.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Roivant Sciences Ltd. said LISRAYA generated $31.0 million in its first 5 weeks after its August 2026 U.S. launch. Consolidated cash, cash equivalents and marketable securities totaled $4.2 billion as of September 30, 2026, supporting cash runway into profitability.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ROIV | +1.7% | +17.9% | +33.3% | +7.1% | +82.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -0.9% | +19.1% | +32.8% | +7.3% | +71.6% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
